Aminoglutethimide

CAS No. 125-84-8

Aminoglutethimide( DL-Aminoglutethimide | NSC 330915 )

Catalog No. M11066 CAS No. 125-84-8

Aminoglutethimide is an aromatase inhibitor that is used in the treatment of advanced BREAST Y.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 48 In Stock
10MG 29 In Stock
25MG 45 In Stock
50MG 62 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Aminoglutethimide
  • Note
    Research use only, not for human use.
  • Brief Description
    Aminoglutethimide is an aromatase inhibitor that is used in the treatment of advanced BREAST Y.
  • Description
    Aminoglutethimide is an aromatase inhibitor that is used in the treatment of advanced BREAST Y.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    DL-Aminoglutethimide | NSC 330915
  • Pathway
    Endocrinology/Hormones
  • Target
    Aromatase
  • Recptor
    Aromatase
  • Research Area
    Endocrinology
  • Indication
    ——

Chemical Information

  • CAS Number
    125-84-8
  • Formula Weight
    232.28
  • Molecular Formula
    C13H16N2O2
  • Purity
    >98% (HPLC)
  • Solubility
    Ethanol: 7 mg/mL (30.13 mM); DMSO: 20 mg/mL (86.1 mM)
  • SMILES
    O=C(C(CC)(C1=CC=C(N)C=C1)CC2)NC2=O
  • Chemical Name
    3-(4-aminophenyl)-3-ethyl-piperidine-2,6-dione

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Neves MA, et al. Eur J Med Chem, 2009, 44(10), 4121-4127.
molnova catalog
related products
  • Formestane

    Formestane was the first selective, type I, steroidal aromatase inhibitor used in the treatment of estrogen-receptor positive breast Y in post-menopausal women.

  • Finrozole

    Finrozole (MPV 2213ad) is a novel selective aromatase inhibitor that is partially reversible for breast development.

  • Letrozole

    Letrozole (INN, trade name Femara) is an oral non-steroidal aromatase inhibitor that has been introduced for the adjuvant treatment of hormonally-responsive breast Y Estrogens are produced by the conversion of androgens through the activity of the aromatase enzyme.